| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
The combined company will operate under the name "ImageneBio, Inc." and will begin trading on Nasdaq under the ticker s...
Wedbush analyst David Nierengarten maintains Ikena Oncology (NASDAQ:IKNA) with a Neutral and lowers the price target from $2...
Ikena Oncology (NASDAQ:IKNA) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.14...
Ikena Oncology (NASDAQ:IKNA) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.21...